We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Elevated Gene Expression Correlates with Prostate Cancer Severity

By LabMedica International staff writers
Posted on 10 Sep 2018
Print article
Image: A micrograph of prostate adenocarcinoma, acinar type, the most common type of prostate cancer (Photo courtesy of Wikimedia Commons).
Image: A micrograph of prostate adenocarcinoma, acinar type, the most common type of prostate cancer (Photo courtesy of Wikimedia Commons).
Elevated expression of the gene ANO7 has been shown to correlate with the severity and possible outcome of prostate cancer (PrCa).

Based on earlier studies showing that genetic signals at 2q37, the location of the prostate specific ANO7 gene were indicators of likelihood of developing prostate cancer, investigators at the University of Turku, Finland) focused on this gene as part of their effort to find germline biomarkers that could predict outcome of the disease.

To investigate, in detail, the associations between the ANO7 gene and PrCa risk and disease aggressiveness, ANO7 from castration resistant tumors was sequenced together with samples from unselected PrCa patients and unaffected males. Two pathogenic variants were discovered and genotyped in 1769 patients and 1711 unaffected males.

Variant rs77559646 showed both risk and association with aggressive PrCa, while high ANO7 expression was independently linked to poor survival. ANO7 genotypes correlated with expression and biochemical relapse, suggesting that ANO7 was a potential PrCa susceptibility gene and that its elevated expression correlated with disease severity and outcome.

"We found that small genetic changes to the ANO7 gene increase a patient's risk of aggressive prostate cancer. One of the current biggest unmet needs in prostate cancer care is being able to diagnose aggressive cancers at an early stage. Genetic testing for ANO7 could help identify these patients sooner and may bring new opportunities for precision oncology in prostate cancer," said senior author Dr. Johanna Schleutker, professor of biomedicine of the University of Turku.

The study was published in the August 29, 2018, online edition of the International Journal of Cancer.

Related Links:
University of Turku

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.